Cryopyrin-Associated Periodic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major cryopyrin-associated periodic syndrome markets are expected to exhibit a CAGR of 4.23% during 2024-2034.
The cryopyrin-associated periodic syndrome market has been comprehensively analyzed in IMARC's new report titled "Cryopyrin-Associated Periodic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cryopyrin-associated periodic syndrome (CAPS) refers to an autoinflammatory disorder characterized by dysregulation of the innate immune system. It encompasses a group of inherited conditions caused by mutations in the NLRP3 gene, resulting in overproduction of interleukin-1? and subsequent inflammation. CAPS manifests with recurring episodes of fever, rash, joint pain, eye redness or conjunctivitis, and neurological issues. These indications often vary in intensity and duration, with some patients experiencing mild, intermittent episodes while others suffer from severe, prolonged manifestations. The diagnosis of CAPS usually requires a combination of clinical symptoms, family history, and laboratory tests. Elevated levels of specific markers like C-reactive protein and serum amyloid A are often observed during flares, supporting the diagnosis. Genetic testing for NLRP3 mutations is a crucial step in confirming the condition. Differential diagnosis is important to distinguish CAPS from numerous other inflammatory diseases, as the treatment approach can vary significantly.
The escalating prevalence of mutations in the NLRP3 gene, which trigger excessive inflammation in tissues and organs, is primarily driving the cryopyrin-associated periodic syndrome market. In addition to this, the inflating utilization of effective treatments, such as interleukin-1 (IL-1) inhibitors, which specifically target the exaggerated IL-1 response and mitigate the inflammatory cascades, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies like physiotherapy and pain management strategies to aid in enhancing the quality of life by addressing mobility issues and minimizing discomfort in individuals suffering from CAPS is further bolstering the market growth. Apart from this, the rising usage of targeted therapies and precision medicine, since they involve tailoring treatment plans to the patient’s genetic makeup, is acting as another significant growth-inducing factor. Additionally, the increasing research in the areas of immunology and genomics, leading to the development of next-generation therapies that can offer lasting relief from the debilitating symptoms of CAPS with minimal side effects, is also augmenting the market growth. Furthermore, the emerging popularity of telemedicine services for remote monitoring and consultations owing to their numerous benefits, like enhancing patient accessibility to specialized care, is expected to drive the cryopyrin-associated periodic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cryopyrin-associated periodic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cryopyrin-associated periodic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cryopyrin-associated periodic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cryopyrin-associated periodic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cryopyrin-associated periodic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current cryopyrin-associated periodic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the cryopyrin-associated periodic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cryopyrin-associated periodic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cryopyrin-associated periodic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cryopyrin-associated periodic syndrome across the seven major markets?
What is the size of the cryopyrin-associated periodic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cryopyrin-associated periodic syndrome?
What will be the growth rate of patients across the seven major markets?
Cryopyrin-Associated Periodic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cryopyrin-associated periodic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cryopyrin-associated periodic syndrome market?
What are the key regulatory events related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by status related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by phase related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the cryopyrin-associated periodic syndrome market?
The cryopyrin-associated periodic syndrome market has been comprehensively analyzed in IMARC's new report titled "Cryopyrin-Associated Periodic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cryopyrin-associated periodic syndrome (CAPS) refers to an autoinflammatory disorder characterized by dysregulation of the innate immune system. It encompasses a group of inherited conditions caused by mutations in the NLRP3 gene, resulting in overproduction of interleukin-1? and subsequent inflammation. CAPS manifests with recurring episodes of fever, rash, joint pain, eye redness or conjunctivitis, and neurological issues. These indications often vary in intensity and duration, with some patients experiencing mild, intermittent episodes while others suffer from severe, prolonged manifestations. The diagnosis of CAPS usually requires a combination of clinical symptoms, family history, and laboratory tests. Elevated levels of specific markers like C-reactive protein and serum amyloid A are often observed during flares, supporting the diagnosis. Genetic testing for NLRP3 mutations is a crucial step in confirming the condition. Differential diagnosis is important to distinguish CAPS from numerous other inflammatory diseases, as the treatment approach can vary significantly.
The escalating prevalence of mutations in the NLRP3 gene, which trigger excessive inflammation in tissues and organs, is primarily driving the cryopyrin-associated periodic syndrome market. In addition to this, the inflating utilization of effective treatments, such as interleukin-1 (IL-1) inhibitors, which specifically target the exaggerated IL-1 response and mitigate the inflammatory cascades, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies like physiotherapy and pain management strategies to aid in enhancing the quality of life by addressing mobility issues and minimizing discomfort in individuals suffering from CAPS is further bolstering the market growth. Apart from this, the rising usage of targeted therapies and precision medicine, since they involve tailoring treatment plans to the patient’s genetic makeup, is acting as another significant growth-inducing factor. Additionally, the increasing research in the areas of immunology and genomics, leading to the development of next-generation therapies that can offer lasting relief from the debilitating symptoms of CAPS with minimal side effects, is also augmenting the market growth. Furthermore, the emerging popularity of telemedicine services for remote monitoring and consultations owing to their numerous benefits, like enhancing patient accessibility to specialized care, is expected to drive the cryopyrin-associated periodic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cryopyrin-associated periodic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cryopyrin-associated periodic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cryopyrin-associated periodic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the cryopyrin-associated periodic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the cryopyrin-associated periodic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current cryopyrin-associated periodic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the cryopyrin-associated periodic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the cryopyrin-associated periodic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the cryopyrin-associated periodic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of cryopyrin-associated periodic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with cryopyrin-associated periodic syndrome across the seven major markets?
What is the size of the cryopyrin-associated periodic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of cryopyrin-associated periodic syndrome?
What will be the growth rate of patients across the seven major markets?
Cryopyrin-Associated Periodic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for cryopyrin-associated periodic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cryopyrin-associated periodic syndrome market?
What are the key regulatory events related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by status related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by phase related to the cryopyrin-associated periodic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the cryopyrin-associated periodic syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - UNMET NEEDS
10 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - MARKETED PRODUCTS
11.1 List of Cryopyrin-Associated Periodic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Ilaris (Canakinumab) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Arcalyst (Rilonacept) - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kineret (Anakinra) - Swedish Orphan Biovitrum
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - PIPELINE DRUGS
12.1 List of Cryopyrin-Associated Periodic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 VTX 2735 - Zomagen Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elranatamab - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Iberdomide - Celgene, Bristol-Myers Squibb
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Masitinib - AB Science
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
16 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - UNMET NEEDS
10 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - MARKETED PRODUCTS
11.1 List of Cryopyrin-Associated Periodic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Ilaris (Canakinumab) - Novartis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Arcalyst (Rilonacept) - Kiniksa Pharmaceuticals/Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Kineret (Anakinra) - Swedish Orphan Biovitrum
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - PIPELINE DRUGS
12.1 List of Cryopyrin-Associated Periodic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 VTX 2735 - Zomagen Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Elranatamab - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Iberdomide - Celgene, Bristol-Myers Squibb
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Masitinib - AB Science
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Nivolumab - Bristol-Myers Squibb/Ono Pharmaceuticals
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Cryopyrin-Associated Periodic Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Cryopyrin-Associated Periodic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Cryopyrin-Associated Periodic Syndrome - Access and Reimbursement Overview
16 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
